Time Is Ripe For Global Action On Orphan Biosimilars
Executive Summary
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
You may also be interested in...
Can Biosimilar Orphans Increase Health System Sustainability In The UK?
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
Libmeldy Gene Therapy Brings Considerable Extra Benefit, Says German Body
With talks to form a new coalition progressing in Germany, the new government, which could take office in early December, is expected to introduce measures to curb pharmaceutical spending. Orphan drugs could be among products targeted.
Gene Therapy Pricing To Come Under Microscope In Germany
The G-BA, the body in charge of Germany’s pricing and reimbursement process, has confirmed that Novartis’s gene therapy Zolgensma (onasemnogene abeparvovec) offers no additional benefit over Biogen’s Spinraza (nusinersen) for treating spinal muscular atrophy.